Intravitreal aflibercept 8 mg in patients from Japan with diabetic macular edema: 48-week subgroup analysis of the PHOTON trial

Improvements in BCVA at Week 48 were generally similar with aflibercept 8 mg versus 2 mg in this subgroup analysis of Japanese and non-Japanese patients with DME, suggesting that the primary findings from PHOTON may be generalized to the Japanese population.

Authors

Institutions

Publication Details

Journal
Japanese Journal of Ophthalmology
Published
2025-12-26
DOI
https://doi.org/10.1007/s10384-025-01271-7
Primary Topic
Retinal Diseases and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Intravitreal aflibercept 8 mg in patients from Japan with diabetic macular edema: 48-week subgroup analysis of the PHOTON trial

Wilfredo Lara, András Seres, Justin Parschauer, Hani Salehi-Had et al.
Japanese Journal of Ophthalmology
Retinal Diseases and Treatments
article

Intravitreal aflibercept 8 mg in patients from Japan with diabetic macular edema: 48-week subgroup analysis of the PHOTON trial

Wilfredo Lara, András Seres, Justin Parschauer, Hani Salehi-Had, Masahiko Shimura, Veeral Sheth, Christopher A. Devine, Paul Conrad, Lawrence J. Singerman, Yasuko Ikegami, Dana Madison Deupree, AMR DESSOUKI, Jamin S. Brown, Adam T. Gerstenblith, Hiroaki Ushida, Nicolas Feltgen, Calvin E. Mein, Hajir Dadgostar, Rafia Bhore, Jordana Fein, Liliya Golas, Vrinda Hershberger, Kunihiko Akiyama, Ashkan Pirouz, Jeffrey J. Tan, Peter H. Win, Julie Gasperini, Jeffrey S. Heier, Masato Kobayashi, Sumit P. Shah, Sunir Joshi, Omar S. Punjabi, Akira Hagiwara, Matthew Pezda, Yoshihiro Yonekawa, Shigeru I. Honda, Ramin Schadlu, Balázs Varsányi, Delia Voronca, Namie Kobayashi, Mitchell J. Goff, Fareed Ali, Peter Morgan-Warren, Genichiro Kishino, Vladimír Korda, M. J. Fenberg, Kazuhiro Kimura, Michel Giunta, Katalin Kiss, James M. Osher, Robert Vitti, Ágnes Kerényi, Hajime Onoe, Atul Jain, Isao Ishikawa, Ursula Schmidt-Ott, Andrea Schulze, Erik Kruger, Alyson J. Berliner, Yoshio Hirano, Adam Berger, Shigeo Yoshida, Joseph M. Googe, Kimberly Reed, Ramanath Bhandari, Dennis M. Marcus, Sobha Sivaprasad, Yenchieh Cheng, Toshinori Murata, Jorge I. Calzada, Vivienne Hau, Eric Jablon, Yoshinori Mitamura, Jason M. Handza, Andres Emanuelli Anzalotta, Dana Cervena, Milan Shah, Yuichiro Ishida, James K. Luu, Jan Ernest, Deepali Varma, Curtis Hagedorn, Kapil Kapoor, Raymond Wee, Richard H. Roe, Kiyoshi Ishii, Scott M. Friedman, James M. Klancnik, Nauman Chaudhry, Annal D. Meleth, R. E. P. Frenkel, Georg Spital, Attila Vajas, Sandeep N. Shah, Yuichi Kaji, Llewelyn Rao, György Bátor, Patrick Higgins, Aderman, Prema Abraham, W. Lloyd Clark, András Papp, Taiji Sakamoto, Matthew Cunningham, Ashish Sharma, Christopher, Sentaro Kusuhara, William Bridges, Tibor Milibák, David M. Brown, Diana Do, Eric Suan, Daniel V. Alfaro, Karen W. Chu, Ken Hayashi, Haruhiko Yamada, David Chow, Masaru Takeuchi, the PHOTON Investigators, Ghassan Ghorayeb, Sumiyo Noge, Geoff Williams, Pamela Weber, Antonio Capone, Charles Wykoff, Christian Brinkmann, Payam Amini, Seong Lee, Philip Ferrone, Kiyoshi Suzuma, Steven Charles, Sergio Leal, Benjamin Thomas, Tetsuo Ueda, Robert Stoltz, Eric Schneider, Paul Hahn, Jiro Kogo, Stuart Burgess, Pradeep Prasad, Sunil Patel, Takashi Kitaoka, Richard Hairston, Hidenori Takahashi, Yoshihiro Takamura, Miroslav Veith, Ankur Shah, Ketan Laud, Edit Tóth-Molnár, Sugat Patel, David Eichenbaum
article en

Abstract

Improvements in BCVA at Week 48 were generally similar with aflibercept 8 mg versus 2 mg in this subgroup analysis of Japanese and non-Japanese patients with DME, suggesting that the primary findings from PHOTON may be generalized to the Japanese population.

Japanese Journal of OphthalmologyVol. 70(1)
Kurume University (JP), Kagoshima University (JP), Regeneron (United States) (US), Tokyo Medical University Hachioji Medical Center (JP), Bayer (Switzerland) (CH), Shinshu University Hospital (JP), Kagawa University Hospital (JP), Aizawa Hospital (JP), Bayer (Japan) (JP), Bayer (Germany) (DE)
Openalex Percentile: Top 29%
Retinal Diseases and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.